

## Kidney and Blood Pressure Research

Kidney Blood Press Res , DOI: 10.1159/000535810

Received: August 11, 2023

Accepted: December 11, 2023

Published online: January 24, 2024

### **In vitro evaluation of the calcification inhibitory properties of Policosanol, Genistein and Vitamin D (Reduplaxin®) either alone or in combination**

Iacobini C, Fassino V, Mazzaferro S, Tartaglione L

ISSN: 1420-4096 (Print), eISSN: 1423-0143 (Online)

<https://www.karger.com/KBR>

Kidney and Blood Pressure Research

#### Disclaimer:

Accepted, unedited article not yet assigned to an issue. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to the content.

#### Copyright:

This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (<http://www.karger.com/Services/OpenAccessLicense>). Usage and distribution for commercial purposes requires written permission.

© 2024 The Author(s). Published by S. Karger AG, Basel

# In vitro evaluation of the calcification inhibitory properties of Policosanol, Genistein and Vitamin D (Reduplaxin®) either alone or in combination.

**Running title: Calcification inhibitory properties of Policosanol, Genistein and Vitamin D**

**Carla Iacobini<sup>1\*</sup>, Valeria Fassino<sup>2\*</sup>, Sandro Mazzaferro<sup>3,4</sup>, Lida Tartaglione<sup>4,^</sup>**

(1) Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy

(2) Department of Experimental Medicine, Sapienza University, Rome, Italy

(3) Department of Translation and Precision Medicine, Sapienza University, Rome, Italy

(4) Department of Internal Medicine and Medical Specialities, Policlinico Umberto I, Rome, Italy

(\*) Equally contributed to this paper

(^)Correspondence: [l.tartaglione@policlinicoumberto1.it](mailto:l.tartaglione@policlinicoumberto1.it)

Department of Internal Medicine and Medical Specialities, Policlinico Umberto I

Via del Policlinico 155, 00161, Rome, Italy

Telephone number: +39 0649978424

## Abstract

**Introduction:** The process of vascular calcification has severe clinical consequences in a number of diseases, including diabetes, atherosclerosis, and end-stage renal disease. In the present study, we investigated the effect of Policosanol, Genistein and Vitamin D separately and in association to evaluate the possible synergistic action on inorganic phosphate (Pi)-induced calcification of Vascular Smooth Muscle Cells (VSMCs)

**Methods:** Primary Human VSMCs were cultured with either Growth Medium or Growth medium Supplemented with Calcium and Phosphorus (Calcification Medium) in combination with Policosanol, Genistein and Vitamin D. Alizarin red staining, Mineralization and the protein expression of RUNX2 and Superoxide Dismutase-2 (SOD-2) were investigated.

**Results:** All three substances tested were effective at reducing osteogenic differentiation of VSMCs in a dose-dependent manner. Poli+Gen, Poli+VitD, Gen+VitD treatment induced a greater inhibition of calcification and RUNX2 expression compared to single compounds treatments. Moreover the association of Poli+Gen+VitD (Reduplaxin®) was more effective at inhibiting VSMCs mineralization and preventing the increase in RUNX-2 expression induced by Calcification Medium but not modified SOD-2 expression.

**Conclusions:** The association of Pol, Gen and Vit D (Reduplaxin®) has an additive inhibitory effect on the calcification process of VSMCs induced in vitro by a pro-calcifying medium.

## Keywords

Vascular calcification, vitamin D, Policosanol, Genistein, VSMCs transdifferentiation

## Introduction

Vascular calcification is an active and multifactorial process regulated by osteo/chondrogenic reprogramming of vascular smooth muscle cells (VSMCs)[1]. This process shares many similarities with bone mineralization[2]. Trans-differentiation of vascular smooth muscle cells (VSMCs) stimulated by various pathological factors, particularly phosphate, is important for vascular calcification[3,4]. During calcification of VSMCs, various stimuli induce the expression of osteogenic markers such as core-binding factor  $\alpha$ -1 (CBFA1, also known as Runx2)[5,6]. Policosanol is a very long saturated fatty alcohol widely found in many plants including sugarcane, rice bran, and corn.

The main function of policosanol is to increase high-density lipoprotein (HDL) cholesterol levels and, by acting as a hypocholesterolemic agent, lower low-density lipoprotein (LDL) cholesterol levels [7,8]. In addition, policosanol is reported to alleviate cardiovascular disease, reduce blood pressure, and inhibit fat production [9-11].

The isoflavones Genistein is a soy-derived phytoestrogen. Some experimental and clinical studies show that in postmenopausal women isoflavones exhibit potential beneficial features against chronic diseases such as cardiovascular disease (CVD) and osteoporosis[12]

Vitamin D is one of the most important steroid hormones in the body. Its predominant function is the regulation of skeletal health and mineral homeostasis through modulating calcium and phosphate metabolism. Vitamin D has also been reported to serve non-skeletal functions, the majority of which are highly implicated in cardiovascular outcomes. Low serum levels of vitamin D, which are prevalent in older adults, have been associated with an increase both in cardiovascular risk and in postural instability (and thus of bone fractures). Several pieces of evidence point to a significant and protective role of vitamin D on the vasculature[13]

In the present study, we investigated the effect of Policosanol, Genistein and Vitamin D (Reduplaxin®) separately and in association to evaluate the possible synergistic action on inorganic phosphate (Pi)-induced calcification of VSMCs

## Materials and methods

### Cell culture and osteogenic trans-differentiation

Primary human aortic smooth muscle cells (HAoSMCs) commercially obtained from Promocell (Heidelberg, Germany) were cultured in Smooth Muscle Cell Growth Medium according to manufacturer's instructions at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub>. In order to induce VSMC osteogenic trans-differentiation, VSMC were seeded into 24-well plates and cultured in growing medium (GM). After confluence, the cells were incubated for 7 or 14 days in DMEM added with 2mM CaCl<sub>2</sub> and 3mM βglycerophosphate (calcifying medium, CM). The calcifying medium was replaced by a fresh medium every 3 days. All the experiments were performed in triplicate using cells between the 3rd and 6th passages

### Cell treatments

To evaluate the inhibition of vascular calcification, the cells were exposed to Policosanol (25-50μg/ml); Genistein (1–10 nM); Vitamin D (25-50 ng/ml) or vehicle (control) during the whole experiment duration. Also, synergistic effects were tested by exposing cells to Policosanol, Genistein and Vitamin D associations

### Analysis of VSMC calcification:

To compare the differences in VSMC calcification among different treatments, we analyzed the presence of calcified nodules using the Osteogenesis Assay Kit (Merck KGaA, Darmstadt, Germany) according to the manufacturer's instructions. In brief, cell monolayers were fixed in 4% paraformaldehyde and stained with 2% Alizarin red solution to visually detect the presence of mineralization. The quantitative analysis of calcified mineral was then performed by the extraction at low pH (10% Acetic Acid) and absorbance value was measured at 405 nm in a microplate reader (Varioskan Lux, Thermofisher)

### Western Blot

Total cell extracts were harvested in RIPA buffer supplemented with protease inhibitors (Roche, Mannheim, Germany) and centrifuged at 14 000 × g for 10 min at 4°C. Total protein was quantified using the Bradford protein assay reagent (Sigma), after which protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene fluoride membrane. The membranes were then blocked with 5% milk prepared in Tris-buffered saline containing Tween 20 and incubated with the specific primary antibodies mentioned below. Signals were detected using enhanced chemiluminescence reagents (Clarity Biorad) according to the manufacturer's protocol. Densitometric analysis of the blotted membrane was performed using a ChemiDoc Imaging System (Bio-Rad laboratories S.r.l. Italy). Runx2 and SOD2 antibodies were obtained from Cell Signaling Technology (Dallas, TX, USA) and β-Actin antibody from Abcam (Cambridge, MA, USA). The primary antibodies used for western blot assay are listed in Table 1.

### Statistical analysis

All experiments were repeated at least three times. Results are expressed as the mean ± standard deviation (SD) of triplicate independent experiments. Statistical analysis was performed using the Student's t-test. Differences between groups were considered significant when  $p < 0.05$

## Results

## *Elevated calcium and phosphate levels promote osteogenic differentiation and calcification of Human VSMCs*

To examine the effect of elevated calcium and phosphate levels on osteogenic differentiation and calcification of Human VSMCs, cells were plated in growth medium (GM) or calcifying medium (CM, GM supplemented with 3mM Pi and 2 mM Ca) for 7 or 14 days. Alizarin Red staining, used to assess the induction of mineralization, showed that calcium deposition was detected in HAoSMCs cultured in CM, but not in GM (Fig 1A). Quantification of Alizarin red staining showed 2.5-fold increment in calcium content in CM-treated cells at day 7 and 9.8-fold increment at day 14 compared with GM-treated cells (Fig 1B). Additionally, we found that Runx2 protein levels were increased by 7.4-fold, in CM-treated VSMCs at day 7 compared with GM-treated cells. (Fig. 1C).

## *Poli, Gen and Vit D attenuate osteogenic differentiation and calcification of HAoSMC*

To identify new agents which could inhibit vascular calcification, HAoSMCs were incubated for 14 days in CM with increasing doses of Poli, Gen, Vit D (25-50 $\mu$ g/ml; 1-10nM; 25-50ng/ml respectively). Alizarin Red Staining quantification showed that all three substances tested were effective at reducing calcium deposition in a dose-dependent manner (Fig 2 A). In detail Poli, Gen reduced calcification by about 40 and 20%, respectively. However, inhibition by Vit D did not reach significance (Fig 2 B). Further, western blot analysis showed that Poli and Gen additions down-regulated Runx2 expression in HAoSMCs growth in CM by about 50 and 45%, respectively. However, addition of Vit D did not reach significance (Fig3 A). Poli, Gen and VitD didn't modify SOD2 expression (Fig. 3 B).

These results suggest that the tested agents may attenuate osteogenic differentiation of VSMCs.

## *Synergistic effect of Policosanol Genistein and Vitamin D*

To evaluate the effect of Poli, Gen and Vit D association in inhibiting HAoSMC transdifferentiation, the cells were cultured in CM added with the following combination: Poli+Gen; Poli+VitD; Gen+VitD; Poli+Gen+VitD. As shown in Fig. 4A,B Poli+Gen, Poli+VitD, Gen+VitD treatment induced a greater inhibition of calcification (respectively 55, 47 and 42%) and RUNX2 expression (respectively 55, 42 and 50%) compared to single compounds treatments. Moreover, the association of Poli+Gen+VitD (Reduplaxin<sup>®</sup>) resulted in a further reduction of HAoSMC calcification and expression of the osteogenic marker RUNX2 even in the presence of a reduced concentration of the single compounds. In detail, the addition of Poli+Gen+VitD combination decreased calcification by 58% as assessed by Alizarin Red staining quantification (from 380  $\mu$ M in the CM to 158  $\mu$ M) and reduced RUNX 2 expression by 57%(Fig.4C)

Conversely, in these conditions, SOD2 protein expression was not significantly affected (data not shown)

## **Discussion**

In the present study, we found that there may be some potential synergistic effect of the association of Poli+Gen+Vit D (Reduplaxin<sup>®</sup>) on the inhibitory effect of the calcium-phosphate induced vascular calcification. Reduplaxin is already present in the Italian registry of food supplements and is in the market since 2018 as oral supplement for cardiovascular health.

Vascular calcification may be considered an osteoblastogenesis-like process that occurs within the artery wall. A great body of evidence shows that it is not a passive event but an active process in which VSMCs play a crucial role.

In essence, vascular calcification is the trans-differentiation of blood vessels into an osteoblastic phenotype and a transformation of vascular tissues into bone-like tissues. This phenomenon typically occurs in ageing people, in diabetics and in renal failure patients[14]. The current knowledge of the pathogenesis of vascular calcification is still incomplete, but highlights the role of deranged calcium and phosphorus metabolism and of the balance between calcification inhibiting and promoting factors.

In particular, it is widely acknowledged that renal failure patients develop a severe type of vascular calcification which is pathogenically linked to the derangements in mineral metabolism and of calcium, phosphate and vitamin D. Available therapies are based on restriction of dietary phosphate load and/or administration of drugs chelating phosphate in the foods[15]. Despite this, more effective strategies are needed. Available data in the literature

indicate that there are several naturally occurring substances that could possibly represent novel adjuvant therapies.

In experimental studies, Policosanol effectively reduced the expression of phosphate-stimulated osteogenic genes and restored the expression of a VSMCs marker like Smooth Muscle alpha-actin [16]

Similarly, in vitro models, Genistein showed a beneficial role at vascular levels by inhibiting the expression of osteogenic markers of calcification in VSMCs[17].

As for vitamin D, its biological role is always under evaluation for potentially relevant clinical effects (besides treatment of osteoporosis) including prevention of vascular calcification through both direct receptor-mediated and indirect biologic effects[13].

To our knowledge, no data describe the potential synergistic effect played by the association of these drugs. Our results clearly indicate that the combination of Poli, Gen, and vitamin D (Reduplaxin®) may attenuate the osteogenic differentiation of VSMCs.

Importantly, our results showed that the association of Poli+Gen+VitD (Reduplaxin®) resulted in a further reduction both of HAoSMC calcification and of the osteogenic marker RUNX2 expression in the presence of reduced concentrations of the single compounds (table 2). It is thus possible to hypothesize that the association treatment could exert additive effects in blunting the process of vascular calcification by positively influencing the intracellular pathways ultimately leading to calcium phosphate deposition in the vessel walls.

The study has limitations. First, we didn't evaluate the expression of ALP, a well-known marker of VSMCs trans differentiation into osteoblast like cells. However, we evaluated the expression of RUNX2, a transcription factor that is a master regulator of the complex gene regulatory network leading to osteoblastogenesis, and to the eventual ALP activity. Second, we did not thoroughly investigate the pathomechanism of the tested substances. In fact, we know from both in-vivo and in-vitro studies, that the inhibition of vascular calcification process can be driven by several mechanisms like: modulation of antioxidant enzymes/inflammatory cytokines [18], direct induction of scavenging ROS [19], or by activation of different pathways involved in insulin-induced genes expression [16].

## Conclusions

The association of Pol, Gen and Vit D (Reduplaxin®) allows dose reduction and has an synergistic inhibitory effect of the calcification process of VSMCs induced in vitro by a pro-calcifying medium.

## Statement of Ethics

Ethics approval and written informed consent were not required due to national guidelines.

## Conflict of Interest Statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

## Funding Sources

This research was funded by Neilos s.r.l

## Author Contributions

Conceptualization, CI, VF, SM and LT; Formal analysis, CI, VF, LT; Funding acquisition, SM; Investigation, CI, VF; Methodology, CI, VF, SM and LT; Project administration SM, LT; Supervision, SM, LT; Validation, CI, VF; Writing – original draft, CI, VF, SM and LT.

## Data Availability Statement

All data generated during this study are included in this article. Further enquiries can be directed to the corresponding author.

## References

1. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. *Circ Res*. 2001 Dec 7;89(12):1147-54.
2. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. *Circulation*. 2008 Jun 3;117(22):2938-48.
3. Karwowski W, Naumnik B, Szczepański M, Myśliwiec M. The mechanism of vascular calcification- a systematic review. *Med Sci Monit*. 2012 Jan;18(1):RA1-11.
4. Giachelli CM. The emerging role of phosphate in vascular calcification. *Kidney int*. 2009 May;75(9):890-7.
5. Sheen CR, Kuss P, Narisawa S, Yadav MC, Nigro J, Wang W, et al. Pathophysiological role of vascular smooth muscle alkaline phosphatase in medial artery calcification. *J Bone Miner Res*. 2015 May;30(5):824-36.
6. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. *Arterioscler Thromb Vascular Biol*. 2004 Jul;24(7):1161-70.
7. Chen JT, Wesley R, Shamburek RD, Pucino F, Csako G. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. *Pharmacotherapy*. 2005 Feb;25(2):171-83.
8. Taylor JC, Rapport L, Lockwood GB. Octacosanol in human health. *Nutrition*. 2003 Feb;19(2):192-5.
9. Arruzazabala ML, Carbajal D, Mas R, Molina V, Valdes S, Laguna A. Cholesterol-lowering effects of policosanol in rabbits. *Biol Res*. 1994;27(3-4):205-8.
10. Cho KH, Bae MA, Kim JR. Cuban sugar cane wax acid and policosanol showed similar atheroprotective effects with inhibition of LDL oxidation and cholesteryl ester transfer via enhancement of high-density lipoproteins functionality. *Cardiovasc Ther*. 2019 Feb 24;2019:8496409.
11. Lee EY, Yoo JA, Lim SM, Cho KH. Anti-aging and tissue regeneration ability of policosanol along with lipid-lowering effect in hyperlipidemic zebrafish via enhancement of high-density lipoprotein functionality. *Rejuvenation Res*. 2016 Apr;19(2):149-58.
12. Rietjens IMCM, Lousse J, Beekmann K. The potential health effects of dietary phytoestrogens. *Br J Pharmacol*. 2017 Jun;174(11):1263-80.
13. Wang J, Zhou JJ, Robertson GR, Lee VW. Vitamin D in vascular calcification: a double-edged sword? *Nutrients*. 2018 May 22;10(5):652.
14. Covic A, Vervloet M, Massy ZA, Torres PU, Goldsmith D, Brandenburg V, et al. Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. *Lancet Diabetes Endocrinol*. 2018 Apr; 6(4):319-31.
15. Mazzaferro S, de Martini N, Cannata-Andía J, Cozzolino M, Messa P, Rotondi S, et al. Focus on the possible role of Dietary sodium, potassium, phosphate, magnesium, and calcium on CKD progression. *J Clin Med*. 2021 Mar;10(5):958.
16. Kim KM, Kim CH, Cho KH, Jang WG. Policosanol attenuates Pi-induced calcification via AMPK-mediated INSIGs expression in rat VSMCs. *Clin Exp Pharmacol Physiol*. 2021 Oct;48(10):1336-45.
17. Shen C, Yuan Y, Li F, Hu Y, Song Y, Zhao S, et al. Mechanism of genistein regulating the differentiation of vascular smooth muscle cells into osteoblasts via the OPG/RANKL pathway *Oncotarget*. 2017 Aug 10;8(44):76857-64.
18. Kim JH, Lim DK, Suh YH, Chang KA. Long-term treatment of cuban policosanol attenuates abnormal oxidative stress and inflammatory response via amyloid plaques reduction in 5xFAD mice. *Antioxidants (Basel)*. 2021 Aug 23;10(8):1321.
19. Zielonka J, Gebicki J, Gryniewicz G. Radical scavenging properties of genistein. *Free Radic Biol Med*. 2003 Oct 15;35(8):958-65.

## Legend of the figures

Figure 1

Osteogenic differentiation of VSMCs: A) Alizarin Red staining of VSMCs cultured in Growth Medium (GM) or Calcifying Medium (CM); B) Quantitative analysis of mineralization; C) Western Blot analysis of protein expression

Figure 2




Dose-dependent inhibition of vascular calcification by Poli, Gen and Vit D : A) Alizarin Red staining of VSMCs cultured in Calcifying Medium alone or added with different concentrations (C1,C2) of Poli (C1=25µg/ml or C2=50 µg/ml) , Gen (C1=1nM or C2=10 nM) and Vit D (C1=25µg/ml or C2= 50µg/ml); B) Quantitative analysis of mineralization in VSMCs cultured in Calcifying Medium alone or added with Poli (50 µg/ml), Gen (10 nM), VitD (50µg/ml)

Figure 3

Effect of Poli, Gen or VitD treatment: WB Analysis of RUNX2 (A) and SOD2 protein expression (B) in VSMCs


Figure 4

Synergistic effect of Poli, Gen, VitD in inhibiting vascular calcification: Alizarin Red staining, quantitative analysis of mineralization and WB of protein expression in A,B) VSMCs growth in calcifying medium alone or added with the following combinations Poli+Gen; Poli+VitD; Gen+VitD (Poli: 50µg/ml; Gen:10nM; VitD: 50ng/ml); C) VSMCs growth in calcifying medium alone or added with the combination of Poli+Gen+VitD (Poli: 30 µg/ml; Gen:5nM; VitD: 50 ng/ml)











**A**



**B**







Accepted Manuscript

**Table 1: List of Primary Antibodies**

| <b>TARGET</b> | <b>HOST</b> | <b>CAT N.</b>            |
|---------------|-------------|--------------------------|
| RUNX2         | Rabbit mAb  | #12556 (Cell Signaling)  |
| SOD2          | Rabbit mAb  | #135141 (Cell Signaling) |
| B-ACTIN       | Mouse mAb   | #5441 (SIGMA Aldrich)    |

Accepted Manuscript

**Table 2: Effects of Poli, Gen and VitD on calcification and osteogenic markers of HAOsMC**

|                         | <b>Reduction of Calcium Deposition</b> | <b>Reduction of Runx2 expression</b> | <b>Alteration of SOD2 expression</b> | <b>Dose-dependence effect</b> |
|-------------------------|--|--------------------------------------|--------------------------------------|-------------------------------|
| <i>Poli</i>             | ++                                     | ++                                   | Absent                               | Yes                           |
| <i>Gen</i>              | ++                                     | ++                                   | Absent                               | Yes                           |
| <i>VitD</i>             | + (*)                                  | ++                                   | Absent                               | Yes                           |
| <i>Poli + Gen</i>       | +++                                    | +++                                  | Absent                               | Not tested                    |
| <i>Poli + VitD</i>      | +++                                    | +++                                  | Absent                               | Not tested                    |
| <i>Gen + VitD</i>       | +++                                    | +++                                  | Absent                               | Not tested                    |
| <i>Pol + Gen + VitD</i> | ++++                                   | ++++                                 | Absent                               | Not tested                    |

(\*) VitD reduced calcium deposition however the reduction did not reach significance.

**Abbreviations:** Poli, Policosanol; Gen, Genistein; VitD, Vitamin D.